$ARQT News
Last published 1d ago
- 1d agoARQTARCUTIS BIOTHERAPEUTICS, INC. (ARQT) - GUGGENHEIM 3RD ANNUAL HEALTHCARE INNOVATION CONFERENCE - ARCUTIS BIOTHERAPEUTICS INCEarnings Call TranscriptsAll right. Welcome, everybody. And thanks for joining us again at Guggenheim's Healthcare Innovation Conference. I'm Seamus Fernandez, one of the senior biopharma analysts here at Guggeheim. And I'm really pleased to be
- 5d agoARQTArcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireWESTLAKE VILLAGE, Calif., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology,
- 5d agoARQTArcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireWESTLAKE VILLAGE, Calif., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company...
- 6d agoARQTArcutis Begins Enrolling Phase 3 Study Evaluating ZORYVE® (roflumilast) Cream 0.3% in Moderate to Severe Atopic DermatitisGlobeNewswireNew INTEGUMENT-3 study to evaluate efficacy, safety, and tolerability of investigational ZORYVE® cream 0.3% in individuals with moderate to severe atopic dermatitisStudy aims to expand once-daily ZORYVE cream treatment
- 1w agoARQTArcutis Biotherapeutics, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 1w agoARQTArcutis Announces Third Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswireContinued strong ZORYVE® (roflumilast) net product revenue growth, with Q3 revenues of $143.9 million, +45% versus Q3 of 2025, and +11% versus Q2 of 2026, driven by strong demand growthRaised 2026 full-year net product
- 2w agoARQTArcutis Appoints Rob Scott, MD to Board of DirectorsGlobeNewswireWESTLAKE VILLAGE, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovation in immuno-dermatology,
- 2w agoARQTArcutis Management to Present at the Guggenheim 3rd Annual Healthcare Innovation ConferenceGlobeNewswireWESTLAKE VILLAGE, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology,
- 3w agoARQTArcutis to Report Third Quarter 2026 Financial Results and Host Conference Call on November 4, 2026GlobeNewswireWESTLAKE VILLAGE, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology,
- 1mo agoARQTArcutis Presents ZORYVE® (roflumilast) Data and Real-World Topical Corticosteroid Research at EADV and Fall ClinicalGlobeNewswirePresentation of data from the INTEGUMENT-INFANT trial of investigational ZORYVE cream 0.05% in infants ages 3 to <24 months, where treatment options remain limitedNew analyses from the ARRECTOR and DERMIS-1/2 trials
- 1mo agoARQTMorgan Stanley 24th Annual Global Healthcare Conference - ARCUTIS BIOTHERAPEUTICS INCEarnings Call TranscriptsAll right. Good afternoon, everyone. Welcome to the session of the Morgan Stanley Global Healthcare Conference. I'm Judah Frommer, one of the SMID biotech analysts here. We're very excited to have the team from Arcutis j
- 1mo agoARQTMorgan Stanley 24th Annual Global Healthcare Conference - ARCUTIS BIOTHERAPEUTICS INCEarnings Call TranscriptsAll right. Good afternoon, everyone. Welcome to the session of the Morgan Stanley Global Healthcare Conference. I'm Judah Frommer, one of the SMID biotech analysts here. We're very excited to have the team from Arcutis j
- 2mo agoARQTArcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireWESTLAKE VILLAGE, Calif., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in
- 2mo agoARQTArcutis Management to Present at the Morgan Stanley 24th Annual Global Healthcare ConferenceGlobeNewswireWESTLAKE VILLAGE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in
- 3mo agoARQTArcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireWESTLAKE VILLAGE, Calif., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology,
- 3mo agoARQTArcutis Announces Second Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswireContinued strong ZORYVE® (roflumilast) net product revenue growth, with Q2 revenues of $129.9 million, +59% versus Q2 of 2025, and +23% versus Q1 of 2026, driven primarily by strong demand growthCompany raising 2026
- 3mo agoARQTArcutis Expands Board of Directors with Appointment of Chris PeetzGlobeNewswireWESTLAKE VILLAGE, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovation in immuno-dermatology,
- 3mo agoARQTArcutis to Report Second Quarter 2026 Financial Results and Host Conference Call on August 5, 2026GlobeNewswireWESTLAKE VILLAGE, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology,
- 3mo agoMBXARQTNAMSGNLXAttovia Therapeutics Appoints John W. Smither to Board of DirectorsGlobeNewswireSAN CARLOS, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Attovia Therapeutics, Inc. ("Attovia" or the "Company"), a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for
- 4mo agoARQTFDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Infants Down to 3 MonthsGlobeNewswireFDA has set a Prescription Drug User Fee Act (PDUFA) target action date of February 23, 2027Application supported by positive results from Phase 2 open-label INTEGUMENT-INFANT study and Phase 1 open-label
- 4mo agoARQTArcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireWESTLAKE VILLAGE, Calif., July 02, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology,
- 4mo agoARQTArcutis Launches New Virtual Health Platform Supporting Access to Care for Individuals Living with Chronic Inflammatory Skin Diseases, Including Approved ZORYVE® (roflumilast) IndicationsGlobeNewswireVirtual health platform offers an additional pathway to care for the more than 45 million people in the U.S. living with eczema, seborrheic dermatitis, and plaque psoriasisConnects eligible individuals with independent,
- 4mo agoARQTFDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children as Young as Age 2GlobeNewswireZORYVE cream 0.3% is the first once-daily, non-steroidal therapy approved for children with plaque psoriasis as young as 2 years of ageZORYVE cream 0.3% is safe, effective, and well-tolerated for use anywhere on the
- 5mo agoARQTArcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireWESTLAKE VILLAGE, Calif., June 05, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology,
- 5mo agoARQTNew Expert Consensus Provides Age-Specific Guidance for Improving Care for Individuals with Genital Psoriasis Published in the American Journal of Clinical DermatologyGlobeNewswireExpert recommendations focused on the diagnosis and management of genital psoriasis across age groups including pediatric, adult, and older populationsThis is the second published manuscript from the Genital Psoriasis
- 5mo agoARQTArcutis Management to Present at Goldman Sachs 47th Annual Global Healthcare ConferenceGlobeNewswireWESTLAKE VILLAGE, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology,
- 6mo agoARQTArcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireWESTLAKE VILLAGE, Calif., May 08, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology,
- 6mo agoARQTArcutis Announces First Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswireQ1 2026 net product revenue for ZORYVE® (roflumilast) was $105.4 million, a 65% increase compared to Q1 2025, and a 17% decrease compared to Q4 2025Continued strong demand for ZORYVE despite typical Q1 seasonality,
- 6mo agoARQTArcutis Submits Supplemental New Drug Application to the FDA for ZORYVE® (roflumilast) Cream 0.05% to Expand Indication for Treatment of Atopic Dermatitis to Infants Down to 3 MonthsGlobeNewswireSubmission supported by data from INTEGUMENT-INFANT Phase 2 open-label study in infants aged 3 months to less than 24 months with mild to moderate atopic dermatitisOnce-daily ZORYVE cream was well tolerated with a safety
- 6mo agoARQTArcutis' ZORYVE® (roflumilast) Cream Receives Strong Recommendation in American Academy of Dermatology First-Ever Pediatric Atopic Dermatitis GuidelinesGlobeNewswireStrong recommendation with high certainty of clinical evidence underscores proven efficacy, safety, and tolerability of ZORYVE cream as a steroid-free topical phosphodiesterase type 4 (PDE4) inhibitorAtopic dermatitis
- 7mo agoARQTArcutis to Report First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026GlobeNewswireWESTLAKE VILLAGE, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology,
- 7mo agoARQT25TH ANNUAL NEEDHAM VIRTUAL HEALTHCARE CONFERENCE - ARCUTIS BIOTHERAPEUTICS INCEarnings Call TranscriptsHi, good morning. My name is Serge Belanger. I'm one of the healthcare analysts at Needham. I want to welcome everybody to Needham's 25th Annual Healthcare Conference. And for our next fireside chat session this morning,
- 7mo agoANVSARQTAVAINTLA+1The Credibility Filter Wall Street Uses to Sort Biotech WinnersGlobeNewswireVANCOUVER, British Columbia, April 08, 2026 (GLOBE NEWSWIRE) -- USANewsGroup.com News Commentary — Biotechs that went public in Q1 2026 raised a median of $287.5 million each; and nearly every one of them carried mid
- 7mo agoARQTINCYPVLAPalvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of SalesGlobeNewswireMr. Taylor brings a strong track record launching multiple high-profile therapies, most recently serving as Senior Vice President, Sales at Arcutis Biotherapeutics (NASDAQ:ARQT), where he led U.S. sales efforts for
- 7mo agoARQTArcutis Management to Present at the 25th Annual Needham Virtual Healthcare ConferenceGlobeNewswireWESTLAKE VILLAGE, Calif., March 31, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology,
- 7mo agoARQTArcutis Presents New Phase 2 Results in Infants with Atopic Dermatitis in Late-Breaking Session Today at the 2026 American Academy of Dermatology Annual MeetingGlobeNewswireInvestigational ZORYVE® (roflumilast) cream 0.05% was well tolerated with safety findings consistent with prior pediatric experience in the INTEGUMENT programZORYVE cream improved signs and symptoms of mild to
- 8mo agoARQTArcutis Announces Publication of Positive Long-Term Safety and Efficacy Data with ZORYVE® (roflumilast) Cream 0.05% for Treatment of Mild-to-Moderate Atopic Dermatitis in Children Ages 2–5 in Pediatric DermatologyGlobeNewswireZORYVE cream 0.05% was safe and well-tolerated, with efficacy that was maintained and improved over time up to 56 weeks of treatmentChildren ages 2-5 who achieved disease clearance and who switched to proactive
- 8mo agoARQTArcutis Announces Promotion of Mas Matsuda to Executive Vice President and Chief Legal Officer to Support Next Phase of GrowthGlobeNewswireWESTLAKE VILLAGE, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology,
- 8mo agoARQTArcutis Begins Enrolling Phase 1a/1b Study Evaluating ARQ-234, a CD200R Agonist, in Healthy Volunteers and Adults With Atopic DermatitisGlobeNewswirePhase 1a/1b, first-in-human study to evaluate safety and tolerability for investigational ARQ-234 in healthy volunteers and adults with moderate to severe atopic dermatitisARQ-234 is a potent fusion-protein agonist of
- 8mo agoARQTArcutis Management to Present at TD Cowen's 46th Annual Health Care ConferenceGlobeNewswireWESTLAKE VILLAGE, Calif., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology,
- 8mo agoARQTArcutis Biotherapeutics, Inc. Q4/FY 2025 Earnings Conference Call - ARCUTIS BIOTHERAPEUTICS INCEarnings Call TranscriptsLadies and gentlemen, thank you for standing by. Welcome to the Arcutis Biotherapeutics, Inc.'s fourth quarter fiscal year 2025 earnings conference call. At this time, all participants are in a listen-only mode. After th
- 8mo agoARQTArcutis Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateGlobeNewswireQ4 2025 net product revenue for ZORYVE® (roflumilast) was $127.5 million, an 84% increase compared to Q4 2024, and a 29% increase compared to Q3 2025Full year 2025 net product revenue for ZORYVE was $372.1 million,
- 8mo agoARQTProfessional Golfer Max Homa Joins Arcutis' Free to Be Me Campaign, Urging Individuals with Seborrheic Dermatitis to Tee Up a Conversation with Their Healthcare Provider About Long-Term TreatmentsGlobeNewswireMax Homa shares his journey with seborrheic dermatitis to encourage others to take control of their symptomsZORYVE® (roflumilast) foam 0.3% is a once-daily, steroid-free, leave-in topical foam uniquely formulated to
- 9mo agoARQTArcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireWESTLAKE VILLAGE, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology,
- 9mo agoARQTArcutis Announces Positive Topline Results for INTEGUMENT-INFANT Phase 2 Trial of ZORYVE® (roflumilast) Cream 0.05% in Infants with Mild to Moderate Atopic DermatitisGlobeNewswire58% of participants achieved a 75% improvement in Eczema Area and Severity Index (EASI-75) with ZORYVE cream 0.05% at Week 4Investigational ZORYVE cream 0.05% was well tolerated and demonstrated a safety profile
- 9mo agoARQTArcutis Biotherapeutics, Inc. Announces Termination of Promotion Agreement with KowaGlobeNewswireWESTLAKE VILLAGE, Calif., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology,
- 9mo agoARQTArcutis to Report Fourth Quarter and Full Year 2025 Financial Results and Present at Upcoming Investor ConferenceGlobeNewswireFourth quarter and full year 2025 investor conference call scheduled for February 25, 2026 at 4:30 p.m. ETArcutis management to present at the Guggenheim Emerging Outlook: Biotech Summit on February 11, 2026 WESTLAKE
- 9mo agoARQTNationwide Survey Underscores Concerns with Use of Topical Steroids and Need for Long-Term Treatment Strategies Facing the 46 Million Americans with Chronic Inflammatory Skin ConditionsGlobeNewswireNearly 9 in 10 adults and parents of children with plaque psoriasis, atopic dermatitis, and seborrheic dermatitis being treated with topical steroids are concerned about side effectsNearly 8 in 10 adults and parents
- 10mo agoARQTArcutis Highlights 2026 Strategic Priorities and Anticipated MilestonesGlobeNewswireContinued strong growth of ZORYVE® (roflumilast) in 2026 with full-year net product sales guidance of $455–$470 millionAdvancement of ZORYVE indication-expansion strategy beginning with ongoing Phase 2
- 11mo agoARQTArcutis Strengthens Board of Directors with New Appointment of Amit Munshi and Honors Retirement of Bhaskar ChaudhuriGlobeNewswireWESTLAKE VILLAGE, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology,